Adherence to antihypertensive medications and associated factors among hypertensive patients in Ethiopia: Systematic review and meta-analysis

Assefa Tola Gemeda1, Lemma Demissie Regassa1, Adisu Birhanu Weldesenbet1, Bedasa Taye Merga2, Nanti Legesse3 and Biruk Shalmeno Tusa1

Abstract
The foundation of controlling hypertension is adherence to antihypertensive medication adherence. This systematic review and meta-analysis aimed to assess the magnitude and associated factors of adherence to antihypertensive medication among adult hypertensive patients in Ethiopia. A comprehensible bibliographic searching was conducted from PubMed, EMBASE, Scopus, and Web of Science core collection. All published and unpublished studies that had been accessible before 31 May 2020, and written in English were eligible. Joanna Briggs Institute assessment tool was used to evaluate the quality of the findings of the included studies. Stata software 16.0 was used to analyze the data. Study-specific estimates were pooled to determine the overall prevalence estimate across studies using a random-effects meta-analysis model. Publication bias and heterogeneity were checked. Fourteen studies with a total of 4938 hypertensive patients were included in the final systematic review and meta-analysis. The pooled prevalence of medication adherence among hypertensive patients in Ethiopia was 65.41% (95% confidence interval: 58.91–71.91). Sub-group analysis shown that the pooled prevalence of medication adherence was the highest (69.07%, 95% confidence interval: 57.83–80.31, $I^2 = 93.51$) among studies using questionnaire technique whereas the lowest in Morisky Medication Adherence Scale eight-items (60.66%, 95% confidence interval: 48.92–72.40, $I^2 = 97.16$). Moreover, medication adherence was associated with the presence of comorbidities (pooled odds ratio = 0.23, 95% confidence interval: 0.07–0.38, $p = 0.030$, $I^2 = 54.9\%$) and knowledge about the disease and its management (pooled odds ratio = 2.98, 95% confidence interval: 1.72–4.24, $p = 0.04$, $I^2 = 55.55\%$) but not with place of residence (pooled odds ratio = 1.22, 95% confidence interval: 0.51–1.93, $p = 0.00$, $I^2 = 76.9\%$). Despite a lack of uniformity among included studies, adherence to antihypertensive medication among the hypertensive population in Ethiopia was moderate. The presence of comorbidities and/or complications reduced the odds of adherence whereas having good knowledge about the disease increased chance of medication adherence among hypertensive patients.

Keywords
Adherence, antihypertensive medication, hypertension, Ethiopia

Date received: 29 July 2020; accepted: 1 December 2020

1Department of Epidemiology and Biostatistics, School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia
2Department of Public Health and Health Policy, School of Public Health, College of Health and Medical Sciences, Haramaya University, Haramaya, Ethiopia
3School of Pharmacy, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia

Corresponding author:
Assefa Tola Gemeda, Department of Epidemiology and Biostatistics, School of Public Health, College of Health and Medical Sciences, Haramaya University, P.O. Box: 138, Dire Dawa, Harar, Ethiopia.
Email: asseharar91@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Hypertension (raised or elevated blood pressure (BP)) is defined as “systolic BP equal to or above 140 mm Hg and/or diastolic BP equal to or above 90 mm Hg.” It is a serious global public health problem that attributes to heart, brain and kidney diseases, and leads to heart attacks and strokes. Hypertension is considered as the leading cardiovascular risk factor as well as the principal attributing factor for global deaths. Moreover, it is also a major cause of premature death worldwide.

Globally, hypertension affects about 1.13 billion people, and two-thirds of them are living in low- and middle-income countries. Every year, hypertension kills about 9 million people worldwide. The prevalence of hypertension in SSA was approximately 80 million in 2000 and it is projected that 150 million will have hypertension by 2025. Based on a systematic review (SR), the prevalence of hypertension in SSA ranged from 14.7% to 69.9% with the pooled prevalence of 30% (95% confidence interval (CI): 27%–34%).

The exact prevalence of hypertension in Ethiopia is not known. Based on a study conducted among federal ministry civil servants, the prevalence of hypertension was 27.3% (95% CI: 23.3%–31%). In addition, a community-based study showed that the prevalence of hypertension among adults in Eastern Ethiopia was 24.43% (95% CI: 21.57–27.28). This study also stated that 51.64% adult hypertensive patients did not know their disease status. A multifactorial approach which requires to manage patients with hypertension can classified into pharmacological therapy and lifestyle modifications. The main components of lifestyle modification are sodium restriction (diet), exercise, moderation of alcohol consumption, smoking cessation, and weight control. Antihypertensive medication adherence is the foundation for attaining hypertension control and the reduction of its complications. One of the growing global health concerns is non-adherence to pharmacological therapy which creates a major obstacle to safe, cost-effective, and effective use of drugs. A comprehensive meta-analysis (MA) indicated that nearly half (45.2%) of hypertensive patients did not adhere to their antihypertensive medication and 83.7% of patients had uncontrolled BP. In developing countries, the prevalence of medication non-adherence among the hypertensive population ranged from 23% to 67.6% with the mean being 47.34%.

Medication adherence or compliance refers “to the act of conforming to the recommendations made by the provider with respect to timing, dosage, and frequency of medication taking.” It can be defined as “the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen.” Adherence is measured over a period of time and reported as a percentage. Multiple factors are playing a significant role in determining the level of adherence to medication among hypertensive patients. These factors can be grouped into a five main domains such as socioeconomic factors, healthcare service–related factors, disease-related factors, therapy-related factors, and patient-related factors.

Since the nature and character of adherence and its associated factors are very complex, a complete understanding is required in order to develop interventional strategies aimed at the improvement of medication adherence. This kind of compressive national information can be obtained by doing a SR and MA. However, there is no SR of the prevalence and factors associated with adherence to antihypertensive medication in Ethiopia. Therefore, the aim of this SR and MA was to determine the overall adherence to antihypertensive medication and the factors associated with medication adherence among adult’s hypertensive patients in Ethiopia.

Methods

Information sources and searching strategies

This SR and MA was registered in PROSPERO with registration number CRD42020159353. A comprehensible bibliographic searching was conducted to identify relevant published research works on the adherence to antihypertensive medications and associated factors among hypertensive patients in Ethiopia. The relevant studies were searched from the databases of PubMed, Excerpta Medica Database (EMBASE), Scopus, and Web of Science Core collection until 31 May 2020. In addition, a manual search was performed to retrieve unpublished studies and gray literature via Google Scholar and other sources like repositories of Ethiopian public universities. After the potential abstracts of the study were reviewed, their full texts were retrieved. In addition, the reference lists of the identified studies were also examined to identify other relevant articles not captured during our search. The search was done using the following search keywords and medical subject headings (MeSH): “adherence,” “compliance,” “Non-adherence,” “associated factors,” “anti-hypertensive medications,” “anti-hypertensive drugs,” “anti-hypertensive agents,” “Hypertension,” and “Ethiopia.”

Eligibility criteria

The included studies were observational studies (cross-sectional, case–control, and cohort studies) that reported the prevalence and factors associated with adherence to antihypertensive medication among adult hypertensive patients in Ethiopia. All published and unpublished studies that had been accessible before 31 May 2020, and written in English were eligible. The excluded studies were studies with poor quality, letters to the editor, reviews, commentaries, editorials, and case series/reports. Moreover, duplicate studies and studies with incomplete data were also excluded. When duplicate studies were encountered, the most comprehensive and/or recent study with the largest sample size was considered.
Description of the outcomes

The outcome variables were adherence and factors associated with adherence to antihypertensive medication. Adherence to antihypertensive medication was defined as “the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen.”

The two investigators (A.T.G. and N.L.) extracted the data independently using a data extraction template from the Joanna Briggs Institute (JBI) 16 quality assessment tool for observational studies. The selected quality of studies was based on internal validity, systematic error and external validity (generalisability). The quality of the observational studies was assessed using the checklist. The authors compared their results in each step of the selection process. Any discrepancy was resolved through discussion or through asking a fourth reviewer (B.T.M.) if consensus could not be reached. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement flow diagram is used to present the overall study selection process.

Critical appraisal of studies

Joanna Briggs Institute (JBI) quality assessment tool for observational studies was used to assess the overall quality of the findings of the included studies. The quality of the study was evaluated by three authors (L.D.R., B.S.T., and A.B.W.) independently using the checklist. Then, based on their point, the studies were categorized as high (score above 80%), moderate (between 60% and 80%), and low (below 60%) quality. The minimum point to be included into the SR was greater than or equal to 60%. The main reason of critically appraising these studies was to assess the internal validity (systematic error) and external validity (generalisability) of studies and to reduce the risk of biases.

Data extraction and recording

The two investigators (A.T.G. and N.L.) extracted the data independently using a data extraction template from the included studies. The extracted items were the last name of the first author, year of the study conducted and published, study design, study setting (rural vs urban), study type (community-based vs hospital-based), the method used to assess medication adherence (self-report (using tools such as Brief Medication Questionnaire, Eight-Item Morisky Medication Adherence Scale (MMAS), and Medication Adherence Report Scale), or pill count, electronic monitoring, pharmacy records, prescription claims, and biological assay), data collection techniques (face-to-face interview vs self-administered), sample size, the total number of cases adherent to antihypertensive medication, mean or median doses taken, mean or median age and age range in years, and the male proportion in the respective studies will also be obtained. In addition, the measure of association (odds ratio (OR) or relative risk with their respective CIs) for each associated factor was extracted and specification made if obtained from a bivariate or multivariate analysis. The accuracy of the data extraction was verified by comparing the results with the data extraction by the remaining three investigators (L.D.R., B.S.T., and A.B.W.), who independently extracted the data in a randomly selected subset of papers (30% of the total).

Risk of bias

Two authors (A.T.G. and B.S.T.) independently screened and evaluated studies using the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement checklist. Visual inspection of the funnel plot was used to explore the publication bias. Besides, Egger’s regression test was carried out to check the symmetry of the funnel plot.

Statistical analysis

The raw numerical data from each study were extracted and recorded on a Microsoft Word, and then exported to an Excel Spreadsheet. Stata software 16.0 was used to analyze the extracted data. An MA of observational studies was conducted, based on recommendations made by Higgins and Thompson. The pooled prevalence of adherence to antihypertensive medications was determined using an MA of the findings from similar studies. Study-specific estimates were pooled to determine the overall prevalence estimate across studies using a random-effects MA model.

Heterogeneity between the included studies was examined using the I^2 statistic. I^2 values of 25%, 50%, and 75% represented low, medium, and substantial heterogeneity, respectively. Therefore, the presence of heterogeneity between studies was assumed if the I^2 statistic is greater than 75%. The source of heterogeneity among the included studies was verified using sensitivity analysis, sub-group analyses, and meta-regressions. Sub-group analysis was performed in case of substantial clinical and/or methodological heterogeneity using selected variables. A difference between sub-groups was considered significant if the p-value is below 5%. Finally, funnel plots and Egger’s test were used to assess
the presence of publication bias. The presence of publication bias was confirmed using a p-value < 10% on Egger’s test.

**Presentation and reporting of results**

The entire process of study screening, selection, and inclusion was depicted with the aid of a flow diagram using the PRISMA guidelines. The PRISMA checklist was also published alongside the final review. First, a narrative synthesis was written to present the main findings of the included studies. Study descriptions and summary (author-year, country, aim, design and population, sample size, and key findings) were compiled using the Microsoft Word. The prevalence of adherence to antihypertensive medication was reported according to the selected variables. In addition, tables and narrative summaries were used to report the risk of bias for every eligible study. Moreover, available data on the identified factors associated with adherence to antihypertensive medication were summarized in tabular form accompanied by a narrative discussion.

**Results**

**Selection of the studies**

A total of 1923 articles were screened from the five scientific databases (PubMed = 185, Scopus = 722, EMBASE = 125, Web of Science Core = 624, and Google Scholar = 267) of which 473 duplicate articles were excluded. The titles and abstracts of 1450 articles were reviewed according to the inclusion criteria and 1419 articles were not related to the topic and were excluded. The full-text papers of 31 articles were retrieved and reviewed for inclusion which resulted in a total of 18 studies eligible for the methodological quality assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment. After excluding four studies with reasons mainly a weak quality score, 14 studies were included in the final assessment.

**Baseline characteristics of studies**

The selected studies were published between 2012 and 2019. Regarding the geographical part of the country, one study was conducted in the north,19 four studies were in the northwest,20,27,30,31 one study was in the northeast,24 three studies were in the central,26,29,32 two studies were in the western,22,23 one study was in the southern,28 and two studies were in the southwest.21,25

Except for the study in Hawassa28 which was an unmatched case-control study, all other studies were hospital-based cross-sectional quantitative in type. Except for the study in Adama,29 the source population were adult hypertensive patients on antihypertensive medication for at least 1 month. But all hypertensive patients on antihypertensive medication were included in the Adama study. The sample size of studies was ranged from 10024 to 160028 subjects, and the total sample sizes included for this review were 4938. Systematic random sampling was the main sampling technique which was used by six studies,20,26,28-30,32, while six studies were included all adult hypertensive patients visiting the chronic follow-up clinic during data collection.19,21,22,24,25,27

Face-to-face interviews with chart review were the main data collection technique used by eight studies19,21,23,25,26,28,30 while five studies22,24,29,31,32 used interview (non-specific) technique and only one study27 used self-administered questionnaires to assess adherence. The overview of the baseline characteristics of the 14 studies are presented in Table 1 (author; region, publication year, study design, study population, sample size, sampling technique, and data collection methods).

**Reported adherence to antihypertensive treatment**

**Methods of assessing adherence.** The aim of eight studies was to assess the magnitude of adherence to antihypertensive medication and associated factors among hypertensive patients,19,23,24 while three studies were aimed to assess the proportion of non-adherence to antihypertensive medication and associated factors among hypertensive patients,19,23,24 one study22 was aimed to assess the patient compliance and associated factors of antihypertensive treatments, another study28 was designed to assess the determinants of adherence to antihypertensive medication, and the remaining study27 was intended to measure the contribution of adverse effects on antihypertensive medications adherence.

The main medication adherence measurement method was MMAS eight-item scale which was used by six studies,19,21,23,26,28,30 MMAS four-item which was used by three studies,20,31,32 and questionnaire technique by five studies.22,24,25,27,29 Some studies which assessed adherence using questionnaire-based technique were also use other additional methods like pill count24 and a questionnaire-based Morisky Green test.25 Based on the medication adherence measurement methods being used, the adherence level was defined in different ways in these studies.

Five studies did not calculate the sample size.19,21,22,24,27 For studies which calculated the sample size, the response rates were ranged from 93.5%23 to 100%20,26,30. The proportion of female hypertensive patients in these studies was ranging from 29.76%28 to 63.3%25 with an overall proportion of 49.63%. Three studies22,28,29 did not report the mean age of the participants. The mean age of the patients in the remaining 11 studies was ranging from 51.5 (± standard deviation (SD) 12.1) to 58.3 years (± SD 13.7) with the overall mean age of 55.13 years. The methods of assessing adherence and reported adherence of these 14 studies are presented in Table 2 (research objective, measurement of adherence, definition of adherence, response rate, sex distribution, and mean age ± SD).

**The pooled prevalence of medication adherence.** The percentage of medication adherence among hypertensive was wide ranging across reports of primary studies in Ethiopia. The
smallest prevalence of medication adherence was 31.4% as reported by the Nedjo study\(^\text{23}\) while the highest prevalence (89.98%) was reported from Gimb\(\text{i}.\)\(^\text{22}\) The overall pooled prevalence of medication adherence among hypertensive patients in Ethiopia was 65.41% (95% CI: 58.91–71.91; Figure 2).

**Sub-group analysis based on the adherence measurement methods.** Sub-group analysis was computed to assess variability in the level of medication adherence in relation to methods used to measure adherence. The medication adherence measurement methods used by primary studies were categorized into MMAS eight-item, MMAS four-item, and questionnaire technique. According to this sub-group analysis, the magnitudes of medication adherence were substantial variable between the primary studies depending on the difference in methods used to measure medication adherence ($I^2 = 95.70\%$). The highest pooled prevalence of medication adherence was observed among studies using questionnaire technique (69.07%, 95% CI: 57.83–80.31, $I^2 = 93.51$), followed by studies using MMAS four-items 68.84% (95% CI: 62.60–75.09, $I^2 = 81.58$). The lowest prevalence (60.66%) was observed among studies using MMAS eight-items to measure medication adherence (95% CI: 48.92–72.40, $I^2 = 97.16$; Figure 3).
Table 1. The baseline characteristics of the primary studies included in systematic review and meta-analysis on adherence to antihypertensive medications and associated factors among hypertensive patients in Ethiopia, 2020.

| Authors                  | Study area          | Geographical region | Publication year | Study design                      | Study population (hypertensive patients who were) | Sample size | Sampling technique               | Data collection technique |
|--------------------------|---------------------|---------------------|------------------|-----------------------------------|--------------------------------------------------|-------------|----------------------------------|--------------------------|
| Ali et al.19             | Northern Ethiopia   | Northern            | 2014             | Prospective cross-sectional study | Adults and on anti-HPT med for at least 6 months | 121         | All (convenient)                 | Face-to-face interview with document review |
| Ambaw et al.20           | Gondar              | Northwest           | 2012             | Institution-based cross-sectional study | Aged ≥18 years and on anti-HPT med                  | 384         | Systematic random sampling technique | Face-to-face interview with document review |
| Asgedom et al.21         | JUSH                | Southwest           | 2018             | Cross-sectional study             | Aged ≥18 years on anti-HPT med for at least 12 months | 280         | All (convenient)                 | Face-to-face interview with document review |
| Bekele22                 | Gimbi               | Western             | 2019             | A hospital-based cross-sectional study | Aged ≥15 years attending medical OPD (all patients) | 127         | A convenience sampling            | Face-to-face interview with document review |
| Berisa and Dedefo23      | Nedjo               | Western             | 2018             | Cross-sectional study             | Aged ≥18 years and on anti-HPT med for at least 12 months | 172         | Consecutive sampling technique   | Face-to-face interview with document review |
| Chelkeba and Dessie24    | Dessie              | Northeast           | 2013             | Cross-sectional convenient study  | Aged ≥18 years and on anti-HPT med for at least 3 months | 100         | All                              | Face-to-face interview (not clearly described) |
| Dego and Bobasa25        | Jimma town          | Southwest           | 2016             | Prospective cross-sectional       | Aged ≥18 years without any comorbidity and on an anti-HPN drug, for at least 3 months | 120         | All non-comorbid HPT patients    | Face-to-face interview with document review |
| Demisew et al.26         | Debre Berhan        | Central             | 2018             | Cross-sectional study             | On anti-HPN drugs follow-up at least 6 months      | 270         | Systematic random sampling method | Face-to-face interview |
| Gebreyohannes et al.27   | UoG                 | Northwest           | 2019             | Institution-based cross-sectional study | Aged ≥18 years and on anti-HPT med for at least 3 months | 249         | All (convenient)                 | Self-administered and chart review |
| Getenet et al.28         | Hawassa             | Southern            | 2019             | Institution-based unmatched case–control study | Aged ≥18 years on anti-HPT treatment at least 1 month | 1600*       | Systematic random sampling       | Face-to-face interview |
| Hareri et al.29          | Adama               | Central             | 2014             | Facility-based cross-sectional study | Adult on anti-HPN medication (all patients)        | 365         | Systematic sampling method       | Interview |
| Mekonnen et al.30        | Northwest           | Northwest           | 2017             | An institution-based cross-sectional quantitative study | Aged ≥18 years and on anti-HPN drugs for at least a month | 409         | Systematic random sampling       | Face-to-face interview with document review |
| Teshome et al.31         | Debre Tabor         | Northwest           | 2017             | Hospital-based cross-sectional study | Aged ≥18 years and on anti-HPT med for at least 3 months | 337         | Simple random sampling            | Interviewer-administered questionnaire with document review |
| Tibebu et al.32          | Addis Ababa         | Central             | 2017             | Institutional-based cross-sectional study | Aged ≥18 years and on anti-HPT med for at least 6 months | 404         | Systematic random sampling       | Interviewer-administered questionnaire with document review |

HPN: hypertension; anti-HPT: antihypertensive; JUSH: Jimma University Specialized Hospital; UoG: University of Gondar; OPD: out-patient department.

*This sample size was used to assess the overall adherence level of all patients in the Hawassa Referral Hospital (HRH) by conducting a hospital-based census. Then based on this finding, cases and controls were identified. The sample size for the case–control study was 289 (96 cases and 193 controls).
Table 2. The methods of assessing adherence and reported adherence of studies included in SR and MA on adherence to antihypertensive medications and associated factors among hypertensive patients in Ethiopia, 2020.

| Authors                    | The objective of the study                                                                 | Adherence measure method | Definition of adherence | Response rate | Male: female, N (%) | Mean age with a range in years | Quality assessment (%) |
|----------------------------|-------------------------------------------------------------------------------------------|--------------------------|-------------------------|---------------|---------------------|-------------------------------|------------------------|
| Ali et al.19               | To assess antihypertensive medication non-adherence and its determinants among patients on follow-up in Ayder Referral Hospital (ARH) and Mekelle General Hospital (MGH) | MMAS 8                   | Not clearly stated      | No SSC        | 46 (38%): 75 (62%) | Mean = 54.7 ± 12.7 (no range) | 83.4%                  |
| Ambaw et al.20             | To assess adherence to antihypertensive therapy and associated factors among HPN patients on follow-up at the University of Gondar Referral Hospital                          | MMAS 4                   | MMAS mean score ≥3     | 100%          | 142 (37%): 242 (63%) | Mean = 56.9 ± 12.8 (no range) | 83.4%                  |
| Asgedom et al.21           | To assess antihypertensive medication adherence and associated factors among adult hypertensive patients | MMAS 8                   | MMAS 8 score ≥6         | No SSC        | 149 (53.2%): 131 (46.8%) | Mean = 55.0 ± 12.7 years       | 79.1%                  |
| Bekele22                   | To assess the patient compliance and associated factors of antihypertensive treatments in hypertensive patients visiting the Gimbi General Hospital | Questionnaire            | Not clearly stated      | No SSC        | 52 (40.9%): 75 (59.1%) | Not calculated                | 83.4%                  |
| Berisa and Dedefo23        | To assess non-adherence-related factors to antihypertensive medications among hypertensive patients on follow-up at the Nedjo General Hospital | MMAS 8                   | MMAS 8 score ≥8         | 93.50%        | 76 (44.2%): 96 (55.8%) | Mean = 51.5 ± 12.1 years       | 79.1%                  |
| Chelkeba and Dessie24      | To assess the magnitude of adherence and the factors associated with non-adherence to antihypertensive medication | Questionnaires (pill count) | 80% was considered as adherence | No SSC        | 69 (69%): 31 (31%) | Mean: 53.88 ± 10.12 (30–72 years) | 83.4%                  |
| Dego and Bobasa25          | To assess adherence to antihypertensive medication and contributing factors among non-comorbid hypertensive patients in two hospitals of Jimma town, southwest Ethiopia | Questionnaire (Morisky Green test) | Adherence: MGT score of ≥3 | 100%          | 44 (36.7%): 76 (63.3%) | Mean: 53.85 ± 12.00 years        | 83.4%                  |
| Demisew et al.26           | To assess the prevalence of adherence to antihypertensive treatment and associated factors among hypertensive patients | MMAS 8                   | MMAS 8: score ≥8         | 99.60%        | 142 (52.4%): 128 (47.4%) | Mean age of 53.7 ± 1.47 years   | 79.1%                  |
| Gebreyohannes et al.27     | To measure the contribution of adverse effects on antihypertensive medication adherence   | Questionnaire            | >80 medication          | No SSC        | 117 (47%): 132 (53%) | Mean: 56.51 ± 11.00 years       | 83.4%                  |
| Getenet et al.28           | To assess the determinants of adherence to antihypertensive medication among hypertensive patients on follow-up in the Hawassa Referral Hospital | MMAS 8                   | MMAS 8 score ≥6         | 100%          | 203 (70.24%): 86 (29.76%) | Not calculated                  | 83.4%                  |
| Hareri et al.29            | To assess the magnitude of adherence and associated factors with antihypertensive treatment among adults on follow-up at the Adama Hospital, 2013 G.C. | Questionnaire            | Scored above mean for medication adherence | 94%          | 178 (48.8%): 187 (51.2%) | Not calculated                  | 68.8%                  |
| Mekonnen et al.30          | To assess adherence level and its determinants for antihypertensive medications among adult hypertensive patients attending the chronic illness clinics of the referral hospitals in northwest Ethiopia | MMAS 8                   | Scored ≥6 points        | 100%          | 236 (57.7%): 173 (42.3%) | Mean: 54.5 ± 13.58 years       | 83.4%                  |
| Teshome et al.31           | To assess adherence to antihypertensive medications and identify associated factors at the Debre Tabor General Hospital, northwest Ethiopia | MMAS 4                   | MMAS mean score ≥3      | 97.4%         | 163 (48.4%): 174 (51.6%) | Mean = 58.3 ± 13.7 years, ranging (23–88) | 83.4%                  |
| Tibebu et al.32            | To assess adherence to prescribed antihypertensive medications and its associated factors | MMAS 4                   | MMAS 4: ≥3 = low adherence; 1 or 2 = medium adherence, and 0 = high adherence | 97%          | 210 (52%): 194 (48%) | Mean: 54 ± 10.77 years           | 71.9%                  |

SR: systematic review; MA: meta-analysis; MMAS: Morisky Medication Adherence Scale; SSC: sample size calculation; MGT: Morisky Green test; HPN: hypertension.
Factors associated with adherence

A total of 12 studies reported AORs for factors affecting adherence or non-adherence. According to World Health Organization (WHO) recommendation, the identified factors associated with medication adherence in the reviewed studies were categorized into five sets of factors or dimensions which included social and economic factors, therapy-related factors, patient-related factors, condition-related factors, and healthcare system-related factors.

Social and economic factors. The social and economic factors that showed significant association with medication adherence in these studies were age, sex, level of education, place of residence, monthly income, and absence of family support (Table 3).

Out of 11 studies that assess the association of hypertensive patient’s age with medication adherence, six studies found an association. The studies did not use the same-age categories. Generally, those studies revealed that older hypertensive patients were more likely to adhere to their medication than younger patients. According to a study in Nedjo, the odds of adherence were 10 times (AOR = 10.0, 95% CI: 1.18–100.0) more likely among older patients (age >55 years) than the young patients (age 18–34 years). The study in Addis Ababa also reported that older (AOR = 4.09, 95% CI: 1.47–11.39) and middle-aged (AOR = 3.15, 95% CI: 1.34–7.37) to be adherent than young adults (21–39), respectively. The study in Adama town showed that middle-aged (46–55 years) patients were 70% less likely (AOR = 0.30, 95% CI: 0.142–0.640) to be adherent to their medication in comparison with older age (age >55 years) patients. But a study by Dego and Bobasa found that middle-aged (40–59 years) patients were more likely to adhere to their medication compared with participants with older (>60 years) patients (p-value = 0.01). On the contrary, the Debre Tabor study stated that older age patients (>60 years) were 67% less likely (AOR = 0.33, 95% CI: 0.11–0.98) to be adherent in compared to younger (age 18–40 years)
gemeda et al.

9

patients. Similarly, the Hawassa study\textsuperscript{28} also reported that young age (18–44 years) and middle-aged patients (45–54 years) were three times (AOR = 3.80, 95% CI: 1.08–13.31) and 2.78 times (AOR = 2.79, 95% CI: 1.01–7.78) more adherent as compared to elderly people (>65). In contrary, studies in northern Ethiopia\textsuperscript{19}, Dessie\textsuperscript{24}, Debre Berhan\textsuperscript{26} University of Gondar\textsuperscript{27}, and northwest Ethiopia\textsuperscript{30} showed that there was no statistically significant association between age and medication adherence.

Three studies indicated that sex had an association with medication adherence\textsuperscript{20,25,32}. All of these studies indicated that female patients were more adherent than males. A study in Addis Ababa\textsuperscript{32} stated that female hypertensive patients were two times (AOR = 2.18, 95% CI: 1.33–3.58) more likely to be adherent than male patients. Similarly, a study by Ambaw et al.\textsuperscript{20} at Gondar revealed that the odds of adherence to antihypertensive treatment were 52% less likely (AOR = 0.48, 95% CI: 0.28–0.82) among male patients than the female patients. However, studies in northern Ethiopia\textsuperscript{19}, Debre Berhan\textsuperscript{26}, Adama\textsuperscript{29}, and Dessie\textsuperscript{24} found no significant association between gender and medication adherence among hypertensive patients.

Two studies showed the relationship between education status and medication adherence\textsuperscript{23,25}. Illiterate and elementary grade hypertensive patients in Nedjo were 85% (AOR = 0.148, 95% CI: 0.022–0.990) and 95% (AOR = 0.046, 95% CI: 0.007–0.855) less likely to be adherent to medications than those who were college and university graduates, respectively\textsuperscript{23}. A similar finding was also reported in Jimma\textsuperscript{25}. Studies in northwest Ethiopia\textsuperscript{19}, Gondar\textsuperscript{20}, Debre Berhan\textsuperscript{26}, Hawassa\textsuperscript{28}, Adama\textsuperscript{29}, northern Ethiopia\textsuperscript{30}, Debre Tabor\textsuperscript{31}, and Addis Ababa\textsuperscript{32} found that the educational level was not a significant contributing factor to adherence.

Three studies showed an association between place of residence and medication adherence\textsuperscript{19,28,31}. The study in Debre Tabor\textsuperscript{31} shown that respondents who lived in urban areas were two times (AOR = 2.10, 95% CI: 1.15–3.85) more likely to adhere to their antihypertensive medication compared to those who lived in rural areas. Similarly, Hawassa\textsuperscript{'}s study\textsuperscript{28} also reported that patients living in urban areas were

Figure 3. Sub-group analysis showing the pooled prevalence of antihypertensive medication adherence based on tools used to assess medication adherence in Ethiopia, 2020.
six times (AOR = 6.84, 95% CI: 3.05–15.36) more likely to be adherent than those living in a rural area. But a study in northern\textsuperscript{19} found that living in the city had an inverse relation with adherence (AOR = 0.184, 95% CI: 0.024–0.597). Many of the reviewed studies, however, stated that there was no association between place of residence and medication adherence.\textsuperscript{20,23,25,26,30}

In Nedjo, those hypertensive patients with low monthly income (<500 Ethiopian birrs) were less likely (AOR = 0.054, 95% CI: 0.006–0.513) to be adherent to their medications than patients with higher monthly income.\textsuperscript{23} But studies in Gondar,\textsuperscript{20} Jimma,\textsuperscript{25} Debre Berhan,\textsuperscript{26} Adama,\textsuperscript{29} and northwest Ethiopia\textsuperscript{30} revealed that the monthly income of the patients had no association with their medication adherence.

Studies in northern Ethiopia also indicated that family support was an important factor associated with medication adherence.\textsuperscript{19} Hypertensive patients who did not get support from family were more likely to have lower adherence to medication as compared to those who have family support (AOR = 0.170, 95% CI: 0.030–0.905). But according to the study in Addis Ababa, having social support had no association with medication adherence.\textsuperscript{32} Except for a study in Jimma,\textsuperscript{25} which showed a statistically significant association between marital status and medication adherence \((p\text{-value} < 0.05)\), no study in Ethiopia showed an association between antihypertensive medication adherence and occupational or marital status of the patients.\textsuperscript{19,20,23,26,29,30,32}

Disease/condition-related factors. Nine studies found significant associations between disease-related factors like comorbidities, complication, stage of hypertension, BP controlled, having symptoms (muscle pain, tiredness, poor sleep) and forget the fullness of their drugs to adherence with antihypertensive medication\textsuperscript{19–21,26–31} (Table 4).

In Addis Ababa, having social support had no association with medication adherence.\textsuperscript{32} Except for a study in Jimma,\textsuperscript{25} which showed a statistically significant association between marital status and medication adherence \((p\text{-value} < 0.05)\), no study in Ethiopia showed an association between antihypertensive medication adherence and occupational or marital status of the patients.\textsuperscript{19,20,23,26,29,30,32}

### Table 3. Social and economic factors that showed significant association with antihypertensive medication adherence among hypertensive patients in Ethiopia, 2020.

| Authors          | Area                   | Outcome variable                              | Socioeconomic factors affecting adherence to antihypertensive medication (AOR and 95% CI) |
|------------------|------------------------|-----------------------------------------------|----------------------------------------------------------------------------------------|
| Ali et al.\textsuperscript{19} | Northern Ethiopia      | Adherence to antihypertensive medication     | Living in Mekelle city (AOR = 0.184, 95% CI: 0.024–0.597) less adherent to medication  |
|                  |                        |                                               | Absence of family support (AOR = 0.170, 95% CI: 0.030–0.905) less adherent to medication |
| Ambaw et al.\textsuperscript{20} | Gondar                | Adherence to antihypertensive medication     | Male (AOR = 0.48, 95% CI: 0.28–0.82) less adherent to medication                      |
| Berisa and Dede\textsuperscript{23} | Nedjo                 | Adherence to antihypertensive medication non-adherence | Greater than 55 years of age (AOR = 0.10, 95% CI: 0.01–0.85) more non-adherent to medication |
|                  |                        |                                               | Elementary level of education (AOR = 21.62, 95% CI: 3.17–147.38) more non-adherent to medication |
|                  |                        |                                               | Monthly income less than 500 birr (AOR = 18.51, 95% CI: 1.95–176.06) more non-adherent to medication |
| Dego and Bobasa\textsuperscript{25} | Jimma town            | Antihypertensive medication adherence        | No multivariable analysis (only \(p\text{-value}\))                                    |
|                  |                        |                                               | Middle-aged (41–60 years old) patients: more likely to adhere to medication \((p\text{-value} = 0.01)\) |
| Getenet et al.\textsuperscript{28} | Hawassa               | Adherence toward antihypertensive treatment  | Age: 18–44 (AOR = 3.80, 95% CI: 1.08–13.31) and 45–54 years (AOR = 2.79, 95% CI: 1.01–7.78) more adherent to medication |
|                  |                        |                                               | Urban residence (AOR = 6.84, 95% CI: 3.05–15.36) more adherent to medication            |
| Harer\textsuperscript{29}          | Adama                 | Adherence status                              | Middle (46–55 years) age (AOR = 0.30, 95% CI: 0.142–0.640) more non-adherent to medication |
| Teshome et al.\textsuperscript{31} | Debre Tabor           | Adherence toward antihypertensive treatment  | Urban residence (AOR = 2.10, 95% CI: 1.15–3.85) more adherent to medication            |
|                  |                        |                                               | Age >60 years (AOR = 0.33, 95% CI: 0.11–0.98) more non-adherent to medication            |
| Tibebu et al.\textsuperscript{32}  | Addis Ababa           | Adherence to prescribed antihypertensive medications | Female (AOR = 2.18, 95% CI: 1.33–3.58) more adherent to medication                      |
|                  |                        |                                               | Middle-aged and older adults (AOR = 3.15, 95% CI: 1.34–7.37) and \(4.09, 95% CI: 1.47–11.39\) more adherent to medication |

AOR: adjusted odds ratio; 95% CI: 95% confidence interval.
Similarly in Jimma University Specialized Hospital (JUSH) patients with comorbidities were 91.7% less likely (AOR = 0.083, 95% CI: 0.033–0.207) to be adherent compared to patients without comorbidities. The Hawassa study also reported that hypertensive patients without comorbidity were three times (AOR = 3.14, 95% CI: 1.48–6.67) more likely to adhere to their medication than patients with comorbidity. However, a study in northwest indicated that hypertensive patients without comorbidity were four times (AOR = 4.36, 95% CI: 1.34–14.11) more likely to adhere to antihypertensive medications than their counterparts. Likewise, a study in Gondar found that patients without comorbidity and patients with only one comorbidity were 2.5 (AOR = 2.50, 95% CI: 1.01–6.21) and almost three (AOR = 2.68, 95% CI: 1.07–6.71) times more likely to be adherent to their medication than patients with two or more comorbidities, respectively. Two studies also indicated that the presence of hypertension-related complications such as heart diseases was associated with medication adherence among hypertensive patients. Hypertensive patients with hypertensive heart disease were 95.4% less likely (AOR = 0.043, 95% CI: 0.03–0.7) to adhere to their antihypertensive therapy than patients without the complication. The Debre Berhan study also revealed that hypertensive patients with comorbid heart disease were 95.7% less likely (AOR = 0.043, 95% CI: 0.03–0.7) to adhere to their antihypertensive treatment than patients without comorbid heart disease. However, a study in Debre Tabor indicated that having comorbidities like diabetes, cardiovascular disease (CVD), or asthma had no association with medication adherence.

### Table 4. Disease condition–related factors that showed significant association with antihypertensive medication adherence among hypertensive patients in Ethiopia, 2020.

| Study ID          | Area                  | Outcome variable                        | Disease condition–related factors affecting adherence to antihypertensive medication (AOR and 95% CI) |
|-------------------|-----------------------|-----------------------------------------|------------------------------------------------------------------------------------------------|
| Ali et al.19      | Northern Ethiopia     | Adherence to antihypertensive medication | Being at the pre-hypertension class of BP (AOR = 0.052, 95% CI: 0.003–0.242) less adherent to medication |
|                   |                       |                                         | Hypertensive heart disease (AOR = 21.737, 95% CI: 1.568–418.428) more non-adherent to medication |
| Ambaw et al.20    | Gondar                | Adherence to antihypertensive medication | Controlled hypertension (AOR = 2.93, 95% CI: 1.73–4.96) more adherent to medication |
|                   |                       |                                         | Without comorbidity (AOR = 2.50, 95% CI: 1.01–6.21) more adherent to medication |
|                   |                       |                                         | Have only one comorbidity (AOR = 2.68, 95% CI: 1.07–6.71) more adherent to medication |
| Asgedom et al.21  | JUSH                  | Antihypertensive medication adherence   | Comorbidity (AOR = 0.083, 95% CI: 0.033–0.207) more likely to be non-adherent |
| Dego and Bobasa25 | Jimma town            | Antihypertensive medication adherence   | No multivariable analysis (only p-value) |
| Demisew et al.26  | Debre Berhan          | Adherence toward antihypertensive treatment | Comorbid heart disease (AOR = 0.043, 95% CI: 0.03–0.7) less adherent to medication |
|                   |                       |                                         | Forget fullness of their drugs (AOR = 0.014, 95% CI: 0.02–0.116) less adherent to medication |
| Gebreyohannes et al.27 | UoG          | Level of adherence to antihypertensive medications | Feel tiredness (AOR = 3.802, 95% CI: 1.723–8.391) more non-adherent to medication |
|                   |                       |                                         | Muscle pain (AOR = 5.199, 95% CI: 1.407–19.214) more non-adherent to medication |
|                   |                       |                                         | Poor sleep (AOR = 4.89, 95% CI: 1.578–15.160) more non-adherent to medication |
|                   |                       |                                         | Symptoms caused them to change their antihypertensive drug taking behavior (AOR = 16.104, 95% CI: 4.164–62.290) more non-adherent to medication |
| Getenet et al.28  | Hawassa               | Adherence toward antihypertensive treatment | No comorbidities (AOR = 3.14, 95% CI: 1.48–6.67) more adherent to medication |
| Hareri et al.29   | Adama                 | Adherence status                        | Controlled BP (AOR = 2.35, 95% CI: 1.15–4.81) more adherent to medication |
| Mekonnen et al.30 | Northwest             | Adherence toward antihypertensive treatment | No comorbidity (AOR = 4.36, 95% CI: 1.34–14.11) more adherent to medication |

AOR: adjusted odds ratio; 95% CI: 95% confidence interval; JUSH: Jimma University Specialized Hospital; UoG: University of Gondar.
The study in northern Ethiopia\textsuperscript{19} found that patients at the pre-hypertension level (BP between 120/80 and 140/90 mm Hg) were 94.8% less likely (AOR = 0.052, 95% CI: 0.003–0.242) to be adherent to their medications than patients with higher BP (>160/100 mm Hg). Those hypertensive patients with controlled BP were three times (AOR = 2.93, 95% CI: 1.73–4.96) higher chance of being adherent to their treatment in Gondar.\textsuperscript{20} In Hawassa, similar findings were reported as patients with controlled BP were two times more likely (AOR = 2.35, 95% CI: 1.15–4.81) adherent than those with uncontrolled BP value.\textsuperscript{28} But the study in northwest Ethiopia stated that adherence to antihypertensive medication is not associated with BP control.\textsuperscript{19,20,23,25–27,30–32}

There was a significant relationship between forgetfulness and medication adherence among hypertensive patients. A study in Debre Berhan found that hypertensive patients who experienced forgetfulness of their drugs were 98.6% less likely (AOR = 0.014, 95% CI: 0.02–0.116) to be adherent.\textsuperscript{26} A study at the University of Gondar\textsuperscript{27} found that the presence of some symptoms significantly decreased the chance of adherence to hypertensive medication. Hypertensive patients who always or usually feel tiredness, muscle pain, and poor sleep were 74% (AOR = 0.263, 95% CI: 0.119–0.580), 81% (AOR = 0.19, 95% CI: 0.052–0.711), and 80% (AOR = 0.204, 95% CI: 0.066–0.634) less likely to be adherent to their antihypertensive medication, respectively. Moreover, this study also reported that the presence of symptoms caused hypertensive patients to change their antihypertensive medication taking behavior and made them less adherent to their medication (AOR = 16.104, 95% CI: 4.164–62.290).

### Therapy-related factors

Eight studies reported significant associations between therapy-related factors and adherence to antihypertensive medications\textsuperscript{21,23–25,27,30–32} (Table 5).

| Study ID            | Area       | Outcome variable                                      | Therapy-related factors affecting adherence to antihypertensive medication (AOR and 95% CI) |
|---------------------|------------|-------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Asgedom et al.\textsuperscript{21} | JUSH       | Antihypertensive medication adherence                  | Combination of antihypertensive medications (AOR = 0.32, 95% CI: 0.144–0.712) more non-adherent to medication |
| Berisa and Dedefe\textsuperscript{23} | Nedjo      | Antihypertensive medication non-adherence              | Long duration on treatment (>5 years) (AOR = 5.41, 95% CI: 1.08–27.22) more non-adherent to medication |
| Chelkeba and Dessie\textsuperscript{24} | Dessie     | Non-adherence to antihypertensive medication           | Experiencing side effect of the medication (AOR = 4.00, 95% CI: 3.567–6.223) more non-adherent to medication |
| Dego and Bobasa\textsuperscript{25}   | Jimma      | Antihypertensive medication adherence                  | No multivariable analysis (only p-value)                                                    |
| Gebreyohannes et al.\textsuperscript{27} | UoG        | Level of adherence to antihypertensive medications     | Believing symptoms are caused by antihypertensive medications (AOR = 3.249, 95% CI: 1.248–8.456) more non-adherent to medication |
| Mekonnen et al.\textsuperscript{30}   | Northwest  | Adherence toward antihypertensive treatment             | On medications for 3 and more years (AOR = 1.89, 95% CI: 1.10–3.35) more adherent to medication |
| Teshome et al.\textsuperscript{31}    | Debre Tabor| Adherence toward antihypertensive treatment             | Taking less than two drugs per day (AOR = 3.04, 95% CI: 1.53–6.06) more adherent to medication |
| Tibebe et al.\textsuperscript{32}     | Addis Ababa| Adherence to prescribed antihypertensive medications   | Taking more than two types of anti-HPN med (AOR = 0.315, 95% CI: 0.118–0.845) less adherent to medication |

AOR: adjusted odds ratio; 95% CI: 95% confidence interval; JUSH: Jimma University Specialized Hospital; UoG: University of Gondar; HPN: hypertension.
Hypertensive patients who experienced side effects of their medications were 75% less likely (AOR = 0.250, 95% CI: 0.161–0.280) to be adherent to their medication than those who did not experience side effects in Dessie.24

Patient-related factors. Eleven studies found significant associations between patient-related factors with adherence to antihypertensive medication.20,21,23–25,30–32 These patient-related factors were as follows: knowledge about hypertension and its treatment, attitude about antihypertensive treatment, lack of information about their medication, regular physical exercise, and alcohol intake (Table 6).

Out of six studies20,23,28,30–32 which assessed the relationship between medication adherence and knowledge about hypertension and its treatment, five of them20,23,28,31,32 found a positive association. The study in Addis Ababa,32 Debre Tabor,31 Gondar,30 and Hawassa28 revealed that hypertensive patients who had good knowledge of hypertensive and its treatment were three times (AOR = 3.378, 95% CI: 1.971–5.789), nine times (AOR = 8.86, 95% CI: 4.67–16.82), six times (AOR = 6.21, 95% CI: 3.22–11.97), and three times (AOR = 3.13, 95% CI: 1.43–6.82) more likely to adhere to their antihypertensive medication, respectively. Similarly, a study in Nedjo found that hypertensive patients with poor knowledge on hypertension and treatment were 86.9% (AOR = 0.131, 95% CI: 0.042–0.403) less likely to be adherent to their medication in comparison with those with good knowledge.23 But studies in northwest Ethiopia reported that there was no statistically significant association between medication adherence and the knowledge status of the patient.30 Hypertensive patients who did not have information about their medication were 88% less likely to be adherent to their prescribed medications in Adama (AOR = 0.12, 95% CI: 0.258–0.583).29

Another important factor associated with medication adherence was the attitude about antihypertensive treatment.
the University of Gondar reported that patients who regu-
respectively.
sive medications than those who had unfavorable attitude,
95% CI: 5.34–18.27) more likely to adhere to antihyperten-
(AOR = 3.23, 95% CI: 1.31–7.97) and 10 times (AOR = 9.88,
sive patients who had favorable attitude were three times
association with medication adherence. A study in
Debre Tabor did not found
alcohol consumption were 89% less likely (AOR = 0.011,
95% CI: 0.004–0.215).23
The association between alcoholic consumption and med-
cation adherence among hypertensive patients was not con-
clusive. JUSH study reported that patients who had a habit of
alcohol consumption were 89% less likely (AOR = 0.011,
95% CI: 0.002–0.079) to be adherent to antihypertensive
treatment.21 In contrast, a study in Debre Tabor did not found
any significant association between alcohol consumption and medication adherence among hypertensive patients.21

**Healthcare system–related factors.** Five studies found an
association between adherence with antihypertensive med-
ication and healthcare-related factors like distance from the
hospital, patient–provider relationship, and cost of medication20,21,24,25,30 (Table 7).

Distance from the hospital had an inconclusive relation-
ship with medication adherence. A study in Gondar20 reported
that as the distance from the hospital decreased, the adher-
ence to medication got improved (AOR = 2.02, 95% CI: 1.19–3.43). Whereas studies in Jimma,25 Adama,29 and
northwest30 reported that distance from the hospital had no
association with medication adherence.

A second healthcare-related factor that shows significant
association with adherence was patient–provider relationships. Study in the northwest showed that patients who had
good patient–provider relationships were four times (AOR = 4.27, 95% CI: 2.32–7.86) more likely to have good
adherence to antihypertensive medication.30 However,
patients who had a poor interaction with the physician were
50% (AOR = 0.50, 95% CI: 0.238–0.957) less likely to
adhere to their antihypertensive medications in Dessie.24
Moreover, a study in Jimma shown that patients who believed
the goodness of health professionals and conditions at health
institutions were more compliant than those who did not.25
This association was not seen in the Gondar study.20

Another non-conclusive health-related factor associated
with adherence was medication cost or charge. Study in
northwest revealed that patients who had got their medica-
tions free of charge or with the low cost was two times
(AOR = 2.06, 95% CI: 1.13–3.76) more likely to adhere to
the medication than those who had got the medication/s with
high cost.30 Similarly, those patients who get medications
freely were 50 times (AOR = 50.0, 95% CI: 8.55–333.33)
more likely to be adherent to their medication in JUSH.21 But
the study in northern, Gondar,20 Debre Berhan,26 and
Hawassa28 found that medication adherence had no associa-
tion with medication cost or charge

### Table 7. Healthcare system–related factors that showed a significant association with antihypertensive medication adherence and among hypertensive patients in Ethiopia, 2020.

| Study ID | Area         | Outcome variable                          | Healthcare system–related factors affecting adherence to antihypertensive medication (AOR and 95% CI)                                                                 |
|---------|--------------|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ambaw et al.20 | Gondar | Adherence to antihypertensive medication | Distance from the hospital (AOR = 2.02, 95% CI: 1.19–3.43) more adherent to medication                                                                                                             |
| Asgedom et al.21 | JUSH   | Antihypertensive medication adherence     | Getting medications freely (AOR = 0.020, 95% CI: 0.003–0.12) more adherent to medication                                                                                                          |
| Chelkeba and Dessie24 | Dessie | Non-adherence to antihypertensive medication | Poor patient–physician interaction (AOR = 2.0, 95% CI: 1.05–4.20) more non-adherence to medication                                                                                       |
| Dego and Bobasa25  | Jimma  | Antihypertensive medication adherence     | No multivariable analysis (only p-value) Believed health professionals and conditions at health institutions good more compliant                                                                 |
| Mekonnen et al.30 | Northwest | Adherence toward antihypertensive treatment | Got the medication/s free of charge or with low cost (AOR = 2.06, 95% CI: 1.13–3.76) more adherent to medication Good patient–provider relationship (AOR = 4.27, 95% CI: 2.32–7.86) more adherent to medication |

AOR: adjusted odds ratio; 95% CI: 95% confidence interval; JUSH: Jimma University Specialized Hospital
meaning that there are no significant differences. Similarly, the confidence interval of the summary estimate (diamond shape) lies entirely to the left of the line-of-no-effect representing a significantly lower adherence among hypertensive patients with comorbidities and complications ($p = 0.030$). Overall, hypertensive patients with comorbidities and/or complications had 77% lower odds of adherence to antihypertensive medications than patients without comorbidities and/or complications (pooled OR = 0.23, 95% CI: 0.07–0.38, $p = 0.030$, heterogeneity $I^2 = 54.9\%$; Figure 4).

Since funnel plot is symmetric, the observed association between adherence to medication and comorbidities in hypertensive patients was not due to publication bias (Figure 5). The Egger regression asymmetry test also demonstrated no statistically significant publication biases (Egger’s test; $b = 1.66, p = 0.143$).

**Association between knowledge and medication adherence.** The association between medication adherence and knowledge of hypertensive patients was assessed by seven studies,\textsuperscript{20,23,28–32} The MA of these seven studies demonstrated an increased odds of adherence to medication among hypertensive patients with good knowledge about their disease and its management. Six of the seven studies independently reported an OR greater than 1. The odds of adherence to antihypertensive medication were three times increased among patients with a good level of knowledge as compared to those with a poor level of knowledge (pooled OR = 2.98, 95% CI: 1.72–4.24, $p = 0.04$, heterogeneity $I^2 = 55.5\%$; Figure 6). The funnel plot appeared asymmetrical (Figure 7) and an Egger’s regression was significant ($b = 2.13, p = 0.07$).

**Association between the place of residence and medication adherence.** Seven studies reported the association between

| ID            | year | ES (95% CI) | Weight |
|---------------|------|-------------|--------|
| Northern Ethiopia | 2014 | 0.05 (0.00, 0.64) | 12.64  |
| Gondar        | 2012 | 0.40 (0.16, 0.99) | 9.19   |
| JUSH          | 2018 | 0.08 (0.03, 0.21) | 24.99  |
| Debre Berhan  | 2018 | 0.04 (0.03, 0.70) | 11.94  |
| Northwest     | 2017 | 0.23 (0.07, 0.75) | 11.84  |
| Adama         | 2014 | 0.50 (0.29, 0.89) | 13.36  |
| Debre Tabour  | 2017 | 1.89 (0.85, 4.19) | 0.83   |
| Hawassa       | 2019 | 0.32 (0.15, 0.68) | 15.21  |
| Overall (1-squared = 54.9%, $p = 0.030$) | | 0.23 (0.07, 0.38) | 100.00 |

NOTE: Weights are from random effects analysis

**Figure 4.** Meta-analysis of the association between medication adherence and comorbidities in hypertensive patients, 2020.

**Figure 5.** Funnel plot of the odds of the association between medication adherence and comorbidities among hypertensive patients, 2020.
adherence to medication and place of residence of hypertensive patients. Two of the seven studies individually reported an OR greater than 1 while one study reported an OR less than 1. However, the overall pooled OR suggested that there was no significant association between medication adherence and place of residence (pooled OR = 1.22, 95% CI: 0.51–1.93, \( p = 0.00 \)). There was also evidence of substantial heterogeneity (\( I^2 = 76.9\% \)) (Figure 8).

Discussion

Nowadays, addressing medication adherence is considered a major issue in hypertension management that needs to emphasize and get special attention. Due to this reason, several studies are carried out to assess the magnitude and associated factors of medication adherence among hypertensive patients in Ethiopia in recent years. After thorough searching and critically evaluating all these studies, we selected 14 studies with a total number of 4938 hypertensive patients. Therefore, this SR and MA synthesized findings of 14 studies that examined the prevalence and factors associated with antihypertensive medication adherence among hypertensive patients in Ethiopia. As per our knowledge, this
is the first SR and MA on this topic in Ethiopia. The result of this review has the utmost significance to improve the quality of care for hypertensive patients by showing the summarized magnitude of adherence and suggesting possible strategies to improve the adherence level.

The percentage of medication adherence among hypertensive patients was varied considerably across reports of primary studies that ranged from 31.4% to 89.98%. The overall pooled prevalence of medication adherence in Ethiopia was 65.41% (95% CI: 58.91–71.91). This finding was higher compared with previous SR and MA in developing countries which stated that 47.34% of the hypertensive population were non-adherent to their medication.13 This variation might be due to the difference in medication assessment tools in primary studies included in reviews. Half of the included studies in our review were used as a self-reported questionnaire-based to measure adherence. People may exaggerate their medication adherence while using self-report as a measuring instrument.

One of the main findings of this review was the considerable differences in the adherence percentages due to the methods applied. Considerable variations ($I^2=95.70\%$) were found in the prevalence of antihypertensive medication adherence based on the type of adherence measurement used in the reviewed studies. For studies using the researcher’s designed questionnaire technique, the pooled prevalence of medication adherence was 69.07% (95% CI: 57.83–80.31, $I^2=93.51$). Whereas for studies using MMAS four-items and MMAS eight-items, the pooled prevalence was 68.84% (95% CI: 62.60–75.09, $I^2=81.58$) and 60.66% (95% CI: 48.92–72.40, $I^2=97.16$), respectively. This MA found that the lowest pooled prevalence was observed among studies using MMAS eight-items. The same result was also reported from

![Figure 8.](image-url) Meta-analysis of the association between medication adherence and place of residence of hypertensive patients, 2020.

![Figure 9.](image-url) Funnel plot of the odds of an association between medication adherence and knowledge of hypertensive patients in Ethiopia, 2020.
Factors associated with antihypertensive medication adherence reported in studies included in this review were diverse and described in different ways across the studies. Since only a limited number of studies reporting comparable factors, it was not possible to make an MA for the main factors affecting adherence. Due to this reason, we only included three selected factors such as place of residence, presence of comorbidity and/or complications, and knowledge about hypertension and its management in our MA. These factors were selected because they were reported by many of the included studies in comparable way.

One of the findings of this review was the effect of age on medication adherence which showed conflicting results. Generally, the reviewed studies reported that older patients had more chances to be adherent to their medication than younger patients, but this finding was not conclusive. The same result was also reported in an SR from developing countries which stated that adherence was significantly lower among younger age hypertensive patients in India, Pakistan, and Palestine.13 Whereas elderly patients in Serbia had a significantly lower level of adherence.15 Similarly, older aged hypertensive patients were more adherent than the younger one based on an SR and MA of non-adherence to antihypertensive medication in low- and middle-income countries.34 This association between age and adherence might be related to other factors like knowledge, durations of illness, and the presence of comorbidities that are directly related to age.

This study revealed that the presence of comorbidity and/or complications reduced the likelihood of medication adherence whereas having good knowledge about hypertension and its management increased the chance of medication adherence in hypertensive patients. However, this review revealed that there was no significant association between medication adherence and place of residence (pooled OR = 1.22, 95% CI: 0.51–1.93).

The presence of comorbidities and/or complications was one of the potential barriers that significantly associated with antihypertensive medication adherence. In this study, hypertensive patients with comorbidities and/or complications had 77% lower odds of adherence to antihypertensive medications than patients without comorbidities and/or complications (pooled OR = 0.23, 95% CI: 0.07–0.38). Another SR based on 25 studies from 15 countries also reported that hypertensive patients with comorbidities were significantly non-adherent to antihypertensive medications 31.6% (95% CI: 10.2–97.5, p = 0.045, I² = 99.1%).12 Similarly, other studies also stated that hypertensive patients with comorbidities have lower chance of adherence to their antihypertensive medications.37–50 The presence of comorbidity influences the medication adherence due to the nature of the comorbidity itself or the medication taken for the comorbidity.50 When hypertensive patients have comorbidities, they are expected to take more medication. This leads to higher pill burden, drug–drug interaction, and medication side effects that can
attribute to reduce the chance of medication adherence. Some comorbidities like depression can impair cognitive function of the patients which in turn affects drug-taking behavior.

Knowledge on hypertension is one of the most crucial components of hypertension management among hypertensive patients. The findings of our review also pointed out that the knowledge of hypertensive patients was one of the factors associated with medication adherence. Hypertensive patients with good knowledge had increased odds of adherence to medication (pooled OR = 2.98, 95% CI: 1.72–4.24, p = 0.04). An SR and MA from developing countries stated that being knowledgeable was correlated with an increased likelihood of being adherent. Many studies also revealed that knowledge on hypertension is a strong and independent determinant of good medication adherence among hypertensive patients. These studies stated that those hypertensive patients with good knowledge on the disease have higher odds of being adherent to their antihypertensive medication than those with poor knowledge. This might be due to those patients with good knowledge have better understanding about the management of the disease, advantage and importance adherence, and consequences of non-adherence.

Implications for policymakers and clinicians

Our SR and MA provides evidence-based information on the magnitude and factors associated with medication adherence among hypertensive patients in Ethiopia. This knowledge is essential for policymakers, healthcare professionals, patients, and researchers who are interested in enhancing antihypertensive medication adherence.

This article could inform policymakers about the current situation of antihypertensive medication adherence in the country which can help to make evidence-based decisions to improve medication adherence and to tackle factors that negatively affect adherence among hypertensive patients. The findings of this review could help healthcare professionals (nurses, physicians, and pharmacists) to identify factors associated with adherence and to develop well-organized interventions to enhance antihypertensive medication adherence in their practice.

The positive association between level of knowledge and adherence implies the need of continuous educational programs in order to improve hypertensive patients’ awareness about the nature of the disease. Healthcare providers should pay special attention to establish a strong relationship with patients in order to increase knowledge regarding risk factors, complications, and management of hypertension. Therefore, training on communication and counseling skills should be provided to the healthcare workers who provide care for hypertensive patients.

Researchers could use the findings of this review to design appropriate medication adherence assessment methods and techniques which can help them to conduct other research works on the same topic. In addition, this review can give insight to researchers in order to assess the effect or impact of each individual factor on antihypertensive medication adherence. Hypertensive patients are also benefited from this review.

Strengths and weaknesses of the review

The comprehensive search strategy was used to identify relevant studies in the main database like PubMed, Scopus, EMBASE, and Web of Science Core. The PRISMA reporting guidelines were strictly followed for identifying, reporting, and synthesizing this SR and MA. The quality of the included studies was also assessed using standardized measurement, and all articles meet the specified criteria.

We have included 14 studies with a total of 4938 hypertensive patients from all parts of the country except the eastern part which can make this review representative of all patients in the country and the conclusions of this review can be generalizable to the whole population of the country. Through pooling the finding of each of the included studies, this MA provides stronger evidence about the magnitude of antihypertensive medication adherence in Ethiopia. The review assessed all the five dimensions of adherence which can give a comprehensive understanding of factors associated with medication adherence in the country. This can help us to identify a large number of factors associated with antihypertensive medication adherence.

Our review has some methodological limitations. First, we limited our literature search to English languages because English is the medium of communication in higher educational institutions in the country and most of the researchers published their studies in English. Still, it is possible that some suitable studies published in other languages may have been missed. Second, among the selected studies, only one case–control study was found. More case–control studies were desirable to identify more important factors associated with medication adherence. Moreover, all of the included studies were health institution–based studies that may not actually reflect the adherence problem in the community. Since all of the included studies were observational studies, our results were prone to selection bias which is inherent to them.

Third, only half of the included studies were used systematic or simple random sampling techniques while the remaining seven studies selected their study participants using a consecutive sampling technique. This can limit the generalizability of the finding of this review to all hypertensive patients in the country. Fourth, some important factors like sex, educational status, income, social support, BP control level, forgetfulness, alcohol consumption, types of medication, patient–provider relationship, distance from the hospital, and cost of medication were exempted from analysis because they were examined only.
by a few studies. In addition, the classification of numeric variables like age, number of pills per day, and number of comorbidities was not uniformly across the studies. As a consequence, the effects of these factors in medication adherence may have not been clearly indicated. Finally, heterogeneity in important aspects of the methodology of the selected studies limits the results that can be drawn from the synthesis of the data.

Conclusion

The antihypertensive adherence level among the hypertensive population in Ethiopia was moderate as only two-thirds of patients were adhering to their medication. This SR and MA provide us very crucial insight into factors associated with medication adherence among hypertensive patients. Generally, the reviewed studies showed that hypertensive patients with older age, females, higher educational status, without comorbidities or complications, taking few pills a day, good knowledge about hypertension, and its treatment and favorable attitude had a higher chance to be adherent to their medication. Since all of the included factors showed a positive, negative, and neutral association with adherence, no conclusive relationship could be established between them and antihypertensive medication adherence in Ethiopia.

This MA also provides evidence that the presence of comorbidities and/or complications reduced the odds of adherence whereas having good knowledge about the disease increased chance of adherence to medication among hypertensive patients in Ethiopia. Health service providers and policymakers should take these factors into account to design appropriate intervention strategies to enhance adherence among hypertensive patients. There is also a lack of uniformity of medication adherence assessment methods and techniques across studies in Ethiopia that make it very difficult to synthesize and understand all necessary factors associated with medication adherence in the country. Therefore, we highly recommended for the adoption of validated, contextualized, and standardized medication adherence screening tools with a common definition of adherence.

Author contributions

A.T.G. contributed to the development of the study concept, designing and running electronic literature search, study selection, data extraction, data synthesis, writing manuscript, and final approval of the version submitted. L.D.R. contributed to the development of the study concept, study selection, risk of bias assessment, revision of the manuscript, and final approval of the version submitted. A.B.W. contributed to the study selection, risk of bias assessment, revision of the manuscript, and final approval of the version submitted. B.T.M. contributed to the study selection, risk of bias assessment, revision of the manuscript, and final approval of the version submitted. N.L. contributed to the study selection, revision of the manuscript, and final approval of the version submitted. All the authors read and approved the final manuscript.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval was not sought for this study because this was a review article and did not involve any patients.

Informed consent

Informed consent was not sought for this study because this was a review article and did not involve any subjects.

ORCID iD

Assefa Tola Gemed }. https://orcid.org/0000-0002-2155-6097

Data availability

All data generated or analyzed during this study are included in this published article.

References

1. WHO. Global non-communicable diseases target: reduce high blood pressure. Geneva, Switzerland: World Health Organization, 2016.
2. WHO. A global brief on hypertension: silent killer, global public health crisis: world health day 2013. Geneva, Switzerland: World Health Organization, 2013.
3. WHO. Hypertension. Geneva, Switzerland: World Health Organization, 2019.
4. van de Vijver S, Akindi H, Oti S, et al. Status report on hypertension in Africa—Consultative review for the 6th session of the African Union Conference of Ministers of Health on NCD’s. Fan Afr Med J 2013; 16: 38.
5. Ataeh F, Erqou S, Kaptoge S, et al. Burden of undiagnosed hypertension in Sub-Saharan Africa: a systematic review and meta-analysis. Hypertension 2015; 65(2): 291–298.
6. Anga K, Dadi AF and Alene KA. Prevalence of hypertension among federal ministry civil servants in Addis Ababa, Ethiopia: a call for a workplace-screening program. BMC Cardiovasc Disord 2015; 15(1): 76.
7. Roba HS, Beyene AS, Mengesha MM, et al. Prevalence of hypertension and associated factors in Dire Dawa city, Eastern Ethiopia: a community-based cross-sectional study. Int J Hypert 2019; 2019: 9.
8. Gosmanova EO and Kovesedy CP. Adherence to antihypertensive medications: is prescribing the right pill enough? Nephrol Dial Transpl 2014; 30(10): 1649–1656.
9. Abebe SM, Berhane Y, Worku A, et al. Prevalence and associated factors of hypertension: a cross-sectional community based study in Northwest Ethiopia. PLoS ONE 2015; 10(4): e0125210.
10. Agbor VN, Takah NF and Aminde LN. Prevalence and factors associated with medication adherence among patients with hypertension in sub-Saharan Africa: protocol for a systematic review and meta-analysis. BMJ Open 2018; 8(3): e020715.
11. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization, 2003.
12. Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs a systematic review and meta-analysis. Medicine 2017; 96(4): e5641.
13. Dhar L, Dantas J and Ali M. A systematic review of factors influencing medication adherence to hypertension treatment in developing countries. Open J Epidemiol 2017; 07: 211–250.
14. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11(1): 44–47.
15. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012; 73(5): 691–705.
16. Porritt K, Gomersall J and Lockwood C. JBI’s systematic reviews: study selection and critical appraisal. Am J Nurs 2014; 114(6): 47–52.
17. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg 2014; 12(12): 1495–1499.
18. Higgins JP and Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539–1558.
19. Ali M, Bekele M and Teklay G. Antihypertensive medication non-adherence and its determinants among patients on follow up in public hospitals in Northern Ethiopia. Int J Clin Trials 2014; 1: 95.
20. Ambaw AD, Alemie GA, Yohannes SM, et al. Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health 2012; 12: 282.
21. Asgedom SW, Atey TM and Desse TA. Antihypertensive medication adherence and associated factors among adult hypertensive patients at Jimma University Specialized Hospital, southwest Ethiopia. BMC Res Notes 2018; 11(1): 27.
22. Bekele F. Non-compliance and its associated factors among hypertensive patients taking anti-hypertensive treatment visiting Gimbi general hospital Western Ethiopia. Open Public Health J 2018; 11: 62–71.
23. Berisa HD and Dedeo MG. Non-adherence related factors to antihypertensive medications among hypertensive patients on follow up at Nedjo General Hospital in west Ethiopia. Open Public Health J 2018; 11: 62–71.
24. Chelkeba L and Dessie S. Antihypertension medication adherence and associated factors at Dessie Hospital, North East Ethiopia, Ethiopia. Int J Res Med Sci 2013; 1(3): 101–107.
25. Dego TR and Bobasa EM. Adherence to anti-hypertensive medication and contributing factors among non-comorbid hypertensive patients in two hospitals of Jimma town, south west Ethiopia. Gulhane Medical Journal 2016; 58(1): 060–066.
26. Demisew T, Mahmud S and Kechalew T. A cross sectional study to observe adherence to antihypertensive treatment and associated factors among hypertensive patient on follow up in Debre Berhan Referral Hospital, North Sho, Ethiopia, 2017. J Cardiovasc Dis Diagnos 2018; 06: 1000321.
27. Gebreyohannes EA, Bhagavathula AS, Abebe TB, et al. Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital. Clin Hypertens 2019; 25: 1.
43. Lee GK, Wang HH, Liu KQ, et al. Determinants of medication adherence to antihypertensive medications among a Chinese population using Morisky Medication Adherence Scale. *PLoS ONE* 2013; 8(4): e62775.

44. Plakas S, Mastrogiannis D, Mantzorou M, et al. Validation of the 8-item Morisky Medication Adherence Scale in chronically ill ambulatory patients in rural Greece. *Open J Nurs* 2016; 6(03): 158.

45. Lam WY and Fresco P. Medication adherence measures: an overview. *Biomed Res Int* 2015; 2015: 217047.

46. Hawkshead J and Krousel-Wood MA. Techniques for measuring medication adherence in hypertensive patients in outpatient settings. *Dis Manag Health Out* 2007; 15(2): 109–118.

47. Algabbani FM and Algabbani AM. Treatment adherence among patients with hypertension: findings from a cross-sectional study. *Clin Hypertens* 2020; 26: 18.

48. Ghembaza MA, Senoussaoui Y, Tani MK, et al. Impact of patient knowledge of hypertension complications on adherence to antihypertensive therapy. *Curr Hypertens Rev* 2014; 10(1): 41–48.

49. Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. *Am J Hypertens* 1997; 10(7 Pt 1): 697–704.

50. Saadat Z, Nikdoust F, Acrab-Sheibihi H, et al. Adherence to antihypertensives in patients with comorbid condition. *Nephrourol Mon* 2015; 7(4): e29863.

51. Abu H, Aboumatar H, Carson KA, et al. Hypertension knowledge, heart healthy lifestyle practices and medication adherence among adults with hypertension. *Eur J Pers Cent Healthc* 2018; 6(1): 108–114.

52. Boima V, Ademola AD, Oduola AO, et al. Factors associated with medication nonadherence among hypertensives in Ghana and Nigeria. *Int J Hypertens* 2015; 2015: 205716.

53. Hashmi SK, Afridi MB, Abbas K, et al. Factors associated with adherence to anti-hypertensive treatment in Pakistan. *PLoS ONE* 2007; 2(3): e280–e.

54. Lulebo AM, Mutombo PB, Mapatano MA, et al. Predictors of non-adherence to antihypertensive medication in Kinshasa, Democratic Republic of Congo: a cross-sectional study. *BMC Res Notes* 2015; 8: 526.

55. Mekonnen GB and Gelayee DA. Low medication knowledge and adherence to oral chronic medications among patients attending community pharmacies: a cross-sectional study in a low-income country. *Biomedi Res Int* 2020; 2020: 4392058.

56. Najjar A, Amro Y, Kitanah I, et al. Knowledge and adherence to medications among Palestinian Geriatrics Living with chronic diseases in the West Bank and East Jerusalem. *PLoS ONE* 2015; 10(6): e0129240.

57. Salama A, Yasin AE-R and Elbarbary W. Medication knowledge as a determinant of medication adherence in geriatric patients, Serse Elian City, Menoufia Governorate, Egypt. *Menoufia Med J* 2017; 30(1): 63–68.